After Barclays and Canaccord Genuity gave Y-Mabs Therapeutics (NASDAQ: YMAB) a Buy rating last month, the company received another Buy,
Category: Healthcare
Oric Pharmaceuticals (ORIC) Gets a Buy Rating from H.C. Wainwright
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Oric Pharmaceuticals (ORIC – Research
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oric Pharmaceuticals (NASDAQ: ORIC), Biospecifics Technologies (NASDAQ: BSTC) and Graybug Vision (NASDAQ: GRAY)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Oric Pharmaceuticals (ORIC – Research
Hookipa Pharma (HOOK) Receives a Buy from Leerink Partners
In a report issued on May 13, Andrew Berens from Leerink Partners initiated coverage with a Buy rating on Hookipa
Intellia Therapeutics (NTLA) Gets a Hold Rating from Oppenheimer
In a report released yesterday, Jay Olson from Oppenheimer maintained a Hold rating on Intellia Therapeutics (NTLA – Research Report).
Why Did Oppenheimer Upgrade Chinook Therapeutics’ Stock?
In a report released yesterday, Justin Kim from Oppenheimer upgraded Chinook Therapeutics (KDNY – Research Report) to Buy, with a
Wedbush Keeps Their Buy Rating on United Therapeutics (UTHR)
In a report released yesterday, Liana Moussatos from Wedbush reiterated a Buy rating on United Therapeutics (UTHR – Research Report),